Ironwood Pharmaceuticals (NASDAQ:IRWD) Downgraded by Zacks Research to Hold

Zacks Research downgraded shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from a strong-buy rating to a hold rating in a research report sent to investors on Wednesday,Zacks.com reports.

Several other equities research analysts have also recently issued reports on the stock. Citigroup raised shares of Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, January 5th. Jefferies Financial Group reissued a “hold” rating and set a $3.70 price objective on shares of Ironwood Pharmaceuticals in a research note on Thursday. Wells Fargo & Company raised their target price on shares of Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a research report on Monday, January 5th. Citizens Jmp lifted their target price on shares of Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the stock a “market outperform” rating in a research note on Thursday. Finally, Craig Hallum raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $4.93.

Ironwood Pharmaceuticals Stock Performance

Ironwood Pharmaceuticals stock opened at $3.66 on Wednesday. The stock has a fifty day moving average of $4.28 and a two-hundred day moving average of $2.80. The company has a market capitalization of $595.41 million, a price-to-earnings ratio of 28.15 and a beta of 0.17. Ironwood Pharmaceuticals has a fifty-two week low of $0.53 and a fifty-two week high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.03). The company had revenue of $47.71 million during the quarter, compared to analysts’ expectations of $86.10 million. Ironwood Pharmaceuticals had a net margin of 8.11% and a negative return on equity of 13.72%. On average, analysts forecast that Ironwood Pharmaceuticals will post 0.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Integrated Wealth Concepts LLC grew its holdings in shares of Ironwood Pharmaceuticals by 21.4% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 3,406 shares during the period. Focus Partners Advisor Solutions LLC lifted its position in Ironwood Pharmaceuticals by 284.6% during the second quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 29,409 shares in the last quarter. LSV Asset Management purchased a new stake in Ironwood Pharmaceuticals during the fourth quarter worth approximately $30,000. Captrust Financial Advisors acquired a new stake in shares of Ironwood Pharmaceuticals in the second quarter worth $32,000. Finally, Jump Financial LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter worth $34,000.

Key Stories Impacting Ironwood Pharmaceuticals

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Management raised FY‑2026 revenue guidance to $450–$475 million and reiterated a strong outlook; LINZESS showed continued demand growth (11% EUTRx), which supports the higher top‑line guide. Ironwood Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Analyst upgrade from Citizens JMP: price target raised to $10 with a “market outperform” rating — a significant bullish signal that can attract buyers and supports the stock’s rally. Benzinga
• Positive Sentiment: The company reiterated 2025 results achievement and provided investor materials (slide deck) and the conference‑call transcript, giving investors more transparency into drivers of the guide and product performance. Slide Deck
• Neutral Sentiment: Full Q4 earnings call transcript and presentation are available for review; these provide detail on cost structure, guidance assumptions and timing that investors will parse for clarity. Earnings Call Transcript
• Negative Sentiment: Q4 results missed expectations: EPS of ($0.01) vs. $0.02 expected and revenue of $47.7M vs. ~$86.1M consensus (revenue down ~47% YoY). The sizable miss and year‑over‑year revenue decline are the primary near‑term negative catalysts. Zacks: Q4 Earnings and Revenues Fall Shy
• Negative Sentiment: A Seeking Alpha piece downgraded the stock after reporting a pipeline setback and an extended timeline for Apraglutide, raising execution and timing risk for future growth catalysts. Seeking Alpha: Downgrading On Pipeline Setback

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.